The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is driving innovation in the data-driven and gene-based individualization of health care. Our groundbreaking work has led to the creation of the BioMe™ Biobank Program and the CLIPMERGE Technology to make genome-informed personalized medicine possible.
More than 33,000 patients throughout the Mount Sinai Health System have signed up for innovative genomic research through BioMe and their Mount Sinai doctors are already using their DNA for better and safer personalized treatment. Our faculty is leading the way in discovering genetic underpinnings of common diseases and in advancing genome-informed medicine.
"Our view of philanthropy is that, first and foremost, we must be a change agent and develop programs which look optimistically to the future. In that regard, the Institute for Personalized Medicine has struck a chord. As with our other programs, our expectations depend on the expertise of people who share our vision. Thus it was, is, and will be with the Institute. We are profoundly grateful for the opportunity to help open new and exciting medical knowledge for the benefit of humankind." - Charles Bronfman
The Institute is supported through a generous gift from The Andrea and Charles Bronfman Philanthropies (ACBP). For more than 20 years, the foundations associated with the ACBP have focused their philanthropic visions on making a difference in Canada, Israel, the United States, and around the Jewish world.